AR
BBIO icon

Advisory Research’s BridgeBio Pharma BBIO Stock Holding History

Advisory Research’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,101
Closed -$1M – 344
2020
Q4 		$1M Buy
14,101
+4,334
+44% +$209K 0.07% 193
2020
Q3 		$366K Buy
+9,767
New +$307K 0.04% 254

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Research's BBIO Position: Q1 2021 in Review

Advisory Research sold out of BridgeBio Pharma (BBIO) in Q1 2021, closing a stake of 14,101 shares — an estimated $1M sold.

Advisory Research first reported a position in BBIO in Q3 2020 and held it in 2 quarters. The position peaked at $1M in Q4 2020. 198 funds tracked by Wall St. Rank hold BBIO as of Q1 2021.

  • Advisory Research reported no remaining BridgeBio Pharma position as of Q1 2021 after selling out during the quarter.
  • Advisory Research sold 14,101 BridgeBio Pharma shares in Q1 2021, an estimated $1M.
  • Advisory Research first reported a position in BridgeBio Pharma in Q3 2020 and held it in 2 quarters.
  • Advisory Research's BridgeBio Pharma position peaked at $1M in Q4 2020.
  • 198 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2021.

Based on Advisory Research's 13F filing for Q1 2021, filed 12 May 2021.